| Name | Title | Contact Details |
|---|
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe
The Palm Tree Group is a Stafford, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Contego Medical, founded in 2005, has developed a family of novel emboli protection devices. The main feature of each device is that the treatment portion (i.e., balloon or stent) is on the same catheter as the embolic protection device, thus coupling the two together. This device can act as an angioplasty balloon with an integrated emboli protection device. If a stent is mounted on the balloon, it can serve as a stent with an integrated emboli protection device. We know that embolization occurs with all angioplasty and stenting procedures. It is usually hard to predict which ones will result in clinical sequalae. Despite knowing that embolization is ubiquitous, embolic protection devices are not used in all procedures as they add complexity, time, and cost. Dedicated devices do not exist for renal intervention, although the majority of physicians say they would use one if it existed. Contego Medical’s family of embolic protection devices represent a paradigm shift in the treatment of cardiovascular disease.
Restructured under new ownership in 2015, TranS1 has emerged stronger than ever – ready to support a product line that provides a foundation for living well, driven by surgeon innovation. Our impressive team includes experienced R&D, Sales and Professional Education professionals. The TranS1 team is focused on resilient and continuous training of its sales force and physician customers, employing best in class training methods that ultimately benefit patients.
Potrero Medical is a predictive health company that is developing the next generation of smart sensors and artificial intelligence.